Document Detail

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
MedLine Citation:
PMID:  17992567     Owner:  NLM     Status:  MEDLINE    
The Clinical Trials described in this article were presented at the Hotline and Clinical Trial Update Sessions of the European Society of Cardiology Congress held in September 2007 in Vienna, Austria. The sessions chosen for this article represent the scope of interest of Cardiovascular Drugs and Therapy. The presentations should be considered preliminary, as further analyses could alter the final publication of the results of these studies. PROSPECT evaluated echocardiographic criteria for optimal selection of patients with moderate to severe heart failure who may benefit from cardiac resynchronisation therapy, however concluded that no single echocardiographic measure can be recommended. EVEREST found that tolvaptan, a vasopressin V(2) antagonist, resulted in early weight reduction and improvement of dyspnoea in patients with acute heart failure, but lacked long term improvement. In ARISE, the anti-oxidant succinobucal did not affect the primary outcome in high risk cardiovascular patients, but improved the combination of cardiovascular death, myocardial infarction and stroke, and diabetic control in diabetics. ALOFT showed that the addition of the renin inhibitor aliskiren to an ACE inhibitor or ARB and a beta-blocker leads to favourable effects on neurohormonal actions in heart failure. FINESSE markedly improved coronary patency before PCI with half-dose reteplase/abciximab in STEMI patients, however without significantly improving short-term outcome. The Prague-8 Study evaluated whether routine clopidogrel administered >6 h pre-angiography would be a safe way to achieve therapeutic drug levels in case a follow-up intervention would be considered immediately, but appeared not justified because of bleeding complications. CARESS in MI showed that high risk patients with evolving STEMI who undergo thrombolytic therapy should undergo PCI early after the thrombolysis. Finally, the ACUITY trial found that in moderate or high risk Non ST elevation ACS patients triaged to PCI, coronary artery bypass graft (CABG) surgery, or medical management, bivalirudin, with or without associated GPIIb/IIIa inhibitor therapy, resulted in a marked reduction of bleeding at 30 days whilst preserving the ischemic and mortality benefit at 1 year follow up.
A Recio-Mayoral; J-C Kaski; J J V McMurray; J Horowitz; D J van Veldhuisen; W J Remme
Related Documents :
7614527 - A comparison of captopril and digoxin in the treatment of patients with mild-to-moderat...
22748807 - Phage therapy-history from twort and d'herelle through soviet experience to current app...
17384437 - Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the eve...
6786457 - Five year follow-up of effects of treatment of mild and moderate hypertension.
19863597 - Faecal diversion in the management of perianal crohn's disease.
9728787 - Laparoscopic partial posterior fundoplication improves poor oesophageal contractility i...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  21     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-06     Completed Date:  2008-02-15     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  459-65     Citation Subset:  IM    
University of London, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / drug therapy
Amides / therapeutic use
Antibodies, Monoclonal / therapeutic use
Benzazepines / therapeutic use
Clinical Trials as Topic*
Fumarates / therapeutic use
Heart Diseases / drug therapy*
Heart Failure / drug therapy,  physiopathology
Immunoglobulin Fab Fragments / therapeutic use
Myocardial Infarction / drug therapy
Peptide Fragments / therapeutic use
Probucol / analogs & derivatives,  therapeutic use
Recombinant Proteins / therapeutic use
Ticlopidine / analogs & derivatives,  therapeutic use
Reg. No./Substance:
0/Amides; 0/Antibodies, Monoclonal; 0/Benzazepines; 0/Fumarates; 0/Hirudins; 0/Immunoglobulin Fab Fragments; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 150683-30-0/tolvaptan; 23288-49-5/Probucol; 502FWN4Q32/aliskiren; 55142-85-3/Ticlopidine; A74586SNO7/clopidogrel; J1J54V24R4/succinobucol; X85G7936GV/abciximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  pH induces thermal unfolding of UTI: an implication of reversible and irreversible mechanism based o...
Next Document:  Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis.